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doi:10.1016/j.gmbhs.2012.02.001Abstract We analyzed the clinical outcome of stage II to IV malignant thymoma. This study
focused on the treatment of 60 cases that combined surgery (biopsy or resection) and radiation
therapy (with or without chemotherapy). Univariate and multivariate analyses of prognostic
factors predicting survival were carried out. There is a statistically significant relationship
between the extent of surgery and the local control (19.4% of relapse after complete resection
vs. 41.2% of relapse after partial resection or biopsy, pZ 0.0001). Mediastinal radiation dose
(50 Gy) had a significant effect in decreasing recurrence (pZ 0.0001) and distant metastasis
(pZ 0.011). The rates of local recurrence (30%) and distant metastasis (25%) justify recom-
mending a higher dose of mediastinal radiation (50 Gy) for patients with malignant thymoma.
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an Genomic Medicine and BiomaIntroduction
Thymomas are the most common form of primary anterior
mediastinal tumors and account for 15e20% of all medias-
tinal cases.1 They are derived from thymic epithelial cellsrker Society. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1 Patient characteristics (nZ 60).
Parameter n %
Age (y)
<55 37 61.7
55 23 38.3
Sex
Male 39 65
Female 21 35
Karnofsky score
60 14 23.3
70 17 28.3
80 24 40
90 5 8.3
Systemic disease
No 43 18
Yes 17 6
MG
No 43 71.7
Yes 17 28.3
Tumor size (cm)
5 9 15
>5, <8 35 58.3
8 16 26.7
Stage
II 19 31.7
III 17 28.3
IV 24 40
Pathology
Type A 4 6.7
Type AB 12 17
Type B1 6 6
Type B2 5 8.3
Type B3 8 13.3
Type C 25 41.7
Resectability
Complete 31 51.7
Partial 9 15
Unresectable 20 33.3
OP way
Biopsy 17 28.3
Sternectomy 31 51.7
VATS 12 20
RT dose (Gy)
<50 15 25
50, <60 30 50
60 15 25
RT field
Mediastinum 33 55
Mediastinumþ SCV 27 45
SCV dose (Gy)
<45 42 70
45 18 30
Table 1 (continued ).
Parameter n %
CT
RT alone 46 76.7
RTþ CT 14 23.3
CTZ computed tomography; MGZmyasthenia gravis;
OPZ operation; SCVZ supraclavicular; RTZ radiotherapy;
VATSZ video-assisted thoracic surgery.
112 M.-Y. Huang et al.and distinguished from thymic lymphomas, germ cell
tumors, and carcinoid tumors.2 Few thymomas are associ-
ated with as many paraneoplatic syndromes, including
myasthenia gravis (MG), pure red cell aplasia, acquired
hypogammaglobulinemia, and connective tissue disor-
ders.1,3 MG is, by far, the most common, being reported in
25e35% of patients with thymoma.4
Several studies have indicated the importance of initial
tumor invasion and the extent of surgical resection as
predictors of recurrence and survival after resection of
a thymoma.5e7 The most widely employed system for
clinical staging at initial presentation is that proposed by
Masaoka et al.8
Although most authors believe that tumor stage at initial
presentation and the extent of surgical resection reliably
predict thymoma prognosis, the findings have been equivocal
when other predictors of prognosis are examined. The
histologic classification of thymoma has remained a subject
of controversy for many years.9 In 1999, the World Health
Organization (WHO) Consensus Committee published a histo-
logic typing system of tumors of the thymus.10 Thymomas are
now stratified into six entities (types A, AB, B1, B2, B3, and C)
on the basis of the morphology of epithelial cells and the
lymphocyte/epithelial cell ratio.
Surgery remains the mainstay of treatment, and radia-
tion and chemotherapy also have been applied widely as
adjuvant and palliative procedures.11,12 In this retrospec-
tive study, we report on the WHO histologic classification
and its clinicopathologic relationship and prognostic rele-
vance in a series of 60 nonmetastatic irradiated malignant
thymomas at Kaohsiung Medical University Hospital in
Taiwan between 1993 and 2007.
The aim of this study was to analyze the long-term
survival and prognostic factors of patients with malignant
thymoma treated by radiation therapy in the light of radi-
ation dose and field.Materials and methods
Study population
Between January 1991 and May 2005, we performed
a retrospective analysis of clinical and histopathological
data on patients radiated for malignant thymoma at our
department. A total of 64 patients with malignant thymoma
underwent mediastinum radiotherapy (RT) with or without
supraclavicular radiation. Four patients were excluded due
RT for malignant thymoma 113to incomplete RT treatment (total dose <40 Gy) or lack of
exact pathologic data. Sixty patients, consisting of 39 men
and 21 women whose age ranged from 14 to 73 years
(median ageZ 50.5 years), had sufficient files of exact
clinical and pathologic data for the current study. The
surgicalepathologic staging system proposed by Masaoka
et al8 was used to describe the invasion of the surrounding
organs. Pathologic examination, based on the WHO classi-
fication system,10 was performed by a single pathologist
who reviewed the hematoxylin and eosin stained sections
without information on the clinical data. Two cases were
“combined thymoma,” which consisted of one type B1 plus
type B2 thymoma and one type B1 plus type B3 thymoma.
We decided to use the major component of the tumor for
the histologic diagnosis. These cases were one type B1 and
one type B3. Final pathologic staging was decided using the
Masaoka staging system. Tumor size was measured by the
largest diameter of the tumor mass on computed tomog-
raphy scan or the resected tumor specimen. MG was related
to disease in 17 patients (28.3%). No patient underwent
preoperative steroid therapy. The characteristics of the
patients are shown in Table 1.
Radiation technique
All patients received RT, while 14 patients were treated by
adjuvant chemotherapy. The irradiated volume of the
mediastinum covered the thymic tumor bed with a 1.5- to
2-cm safe margin. RT was performed with a 6- or 10-MV
linear accelerator (Varian, Connecticut, USA). The treat-
ment volume was encompassed via anteroposterior
opposing portals (equal weighting or anterior weighting 2/3
or 3/4) or a single anterior portal, anterior wedge pair
portals, and reduced irradiation with spinal cord shielding
was administered from 40 to 45 Gy. The median radiation
dose to the mediastinum was 52 Gy (40e62.2 Gy). Supra-
clavicular radiation was performed in 27 patients via 6 MV
photon with anterior portal (median doseZ 45 Gy; range
40e60 Gy). The daily fraction was 1.8e2 Gy, 5 days a week.
Adjuvant chemotherapy
Adjuvant chemotherapy was performed in selected cases of
patients with thymic carcinoma and/or stage III and IV not
radically resected. We chose not to radically resect those
tumors with wide involvement of great mediastinal vessels
or other major structures, using clinical and radiological
criteria and, in a few cases, even an invasive approach
[video-assisted thoracic surgery (VATS) or anterior media-
stinotomy]. The chemotherapy regimen was administered
to 14 patients [ifosfamide, cisplatin, and etoposide (64);
cisplatin, etoposide and paclitaxel (6/14); cyclophosphamide,
pharmarubicin, and cisplatin (2/14)].
Follow-up for all patients was conducted until death or
end of the study. The median follow-up period is 3.7 years
(range 2.06e14.66 years). The response, recurrence, or
distant metastasis was assessed by serial examinations
including chest plain film, computed tomography scan,
abdominal sonography, or bone scan. Survival time was
estimated from the start of RT. Follow-up information with
respect to survival was available in our study.Statistical analysis
The linear regression model by Pearson was employed to
identify the correlation between variables. A p value less
than 0.05 was considered statistically significant.
Association between categorical variables was deter-
mined by using the t-test and chi-square test. The method
of KaplaneMeier was used for the analysis of overall
survival and freedom from relapse (disease-free survival),
and the log-rank test for comparisons of survival (age: <55
years, 55 years; sex; Karnofsky scale; Masaoka staging
system: II, III, and IV; WHO histologic classification: A, AB,
B1, B2, B3, and B3 versus C and others; tumor size;
completeness of resection; surgery way; presence of MG or
other systemic disease; dose and field of radiation; with
and without chemotherapy) by SPSS for Windows (version
11.0.1). Significance was defined as p< 0.05. Deaths as
a result of MG or unrelated disease were excluded.Results
At the end of follow-up, 24 (40%) patients had died. The
median overall survival period from start of RT was 3.7
years for all patients. The median disease-free survival
period was 6.29 years from start of RT. The overall actuarial
5- and 10-year survival rate was 41.7% and 11.7%, respec-
tively (Fig. 1).
The operative approach used was sternotomy in 31
(51.7%) patients and VATS in 12 (20%). No intraoperative or
postoperative mortality occurred; five patients had post-
operative complications: four chest pain and one dyspnea.
The actuarial 5- and 10-year survival rate was 66.7% and
16.1% for patients who had radical resection, 22.2% and
22.2% for those who had incomplete resection, 5% and 0%
for those who had biopsy, respectively. Patients who
underwent radical resection showed a significantly higher
survival rate than those who received incomplete resection
or biopsy (pZ 0.0001).
The invasive tumors was extended to pleura in 15 cases,
to the pericardium in 22 cases, to the great vessels in 16
cases, to the lung in 24 cases, to the chest wall in six cases,
and to the diaphragm in one case. Tumors with invasion to
neighboring organ(s) were noted in 45 (75%) cases; type C
was more invasive than types A, AB, B1, B2, and B3, and
stage IV was more invasive than stages II and III, as shown in
Table 2.
Of the 60 patients, 58 (97%) tolerated RT well and
completed the course as scheduled except for one patient
who had chest pain that interrupted treatment for 2 weeks
and another patient who had fever and dysphagia and took
rest for 1 and ½ weeks. The most common symptoms during
RT courses were cough (35/60, 58%), dysphagia (31/60,
52%), dermatitis (14/60, 23%), chest pain (11/60, 18%),
dyspnea (9/60, 15%), nausea (6/60, 10%), and fever (2/60,
3%). Four patients (7%) had radiation pneumonitis after
completion of treatment, and symptoms were relieved
after supportive treatment. Mediastinal RT was adminis-
tered in 33 patients (55%), and mediastinum with supra-
clavicular RT was administered in 27 patients (45%).
Mediastinum RT was more applied in stage IV (17/33, 50%),
and mediastinum with supraclavicular RT was more applied
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Figure 1 Survival curves for entire patient populations.
114 M.-Y. Huang et al.in stage II (12/27, 44%), with pZ 0.0273. Comparison of
mediastinal RT with mediastinum combined with supra-
clavicular RT yielded statistically significant results
(pZ 0.0208), as shown in Table 3.
Eighteenpatientsdevelopedrecurrence;unresectableand
type C cases had higher recurrent rates. The relationship
between histological subtypes, resectability, adjuvant
chemotherapy, and recurrence is shown in Table 4. Fifteen
patients developed distant metastasis: four had bone metas-
tasis, three had brain metastasis, three had liver metastasis,
one had pararenal metastasis, one had lung metastasis,
one patient developed bone, liver, and lung metastases, one
patient developed bone and brain metastases, and one
patient developed bone and neck lymph node metastases.
Analysis of the prognostic value of various factors
showed statistical significance as shown in Table 5. Prog-
nostic factors were statistically significant including WHO
histologic subtype, Masaoka clinical staging, Karnofsky
score, surgery way, resectability, RT field, RT dose, RT
fraction, and adjuvant chemotherapy. Mediastinal radiation
dose (50 Gy) had a significant effect in decreasing recur-
rence (pZ 0.0001) and distant metastasis (pZ 0.011).
Mediastinum and supraclavicular fossa irradiation had
a statistically significant impact in decreasing distantTable 2 Histologic subtypes and the relationship with
tumor invasion.
Histologic
subtype
II III IV Total Cases of invasion
to neighboring organ
A 2 0 2 4 2 (50%)
AB 7 3 2 12 6 (50%)
B1 3 2 1 6 4 (67%)
B2 2 1 2 5 3 (60%)
B3 3 2 3 8 6 (75%)
C 2 9 14 25 24 (96%)
Total 19 17 24 60 45 (75%)metastasis (pZ 0.0149), but no statistically significant
effect in recurrence (pZ 0.1492).
Discussion
Several studies have been performed to identify the prog-
nostic factors to program the most adequate therapeutic
strategy for thymic epithelial tumors.7,13e15 Surgery is the
best treatment in patients with early stage of thymic
epithelial tumorsand leads toa good long-termsurvival.7,13,14
In the advanced stages, a multidisciplinary approach is pref-
erable, even if the prognosis seems to depend largely on the
ability to perform a radical resection.
In a study conducted on a large number of patients,
Regnard et al13 identified the completeness of resection as
the only significant independent prognostic factor at
multivariate analysis and, on the basis of their results, they
proposed to include this factor in a modified clin-
icalepathologic staging system of thymomas. In our expe-
rience, patients who underwent radical resection had
a higher 5- and 10-year survival rate (66.7% and 16.1%) than
patients who received incomplete resection (22.2% and
22.2%) or biopsy (5% and 0%). In addition, surgical
approaches have evolved recently. We found that patients
who underwent VATS had a better prognosis than those who
had undergone sternectomy.
Regarding the surgicalepathologic staging system
proposed by Masaoka et al, several authors agree that it is
the best prognostic factor for thymic epithelial tumors
predicting long-term survival.6e8,16,17 We confirm this thesis
because, in our series, we found a significantly better
survival rate in stage II than in stage III and IV cases (5-year
survival: 63% and 22%, respectively, pZ 0.0001).
Meanwhile, the prognostic relevance of histology is still
under debate, due to the numerous histological classifica-
tions4 that add to the confusion and make the analysis and
comparison of various results difficult. In 1999, the WHO
Consensus Committee published a new classification system
regarding the criteria to distinguish the different thymic
Table 3 Comparison with mediastinum with or without supraclavicular RT.
Mediastinum
(nZ 33)
Mediastinum and SCV
(nZ 27)
p
n % n %
Pathology
1 12 38.24 13 48.15 0.361
Others 21 61.76 14 51.85
Stage
II 7 20.59 12 44.44 0.0273
III 9 29.41 8 29.63 0.2565
IV 17 50 7 25.93 0.0292
Sex
Female 10 32.35 11 40.74 0.5016
Male 23 67.65 16 59.26
Karnofsky score
60 11 35.29 3 11.11 0.1255
70 9 26.47 8 29.63
80 9 26.47 15 55.56
90 4 11.76 1 3.7
Systemic disease
Yes 8 23.53 9 33.33 0.4002
No 25 76.47 18 66.67
Age (y)
<55 21 64.71 16 59.26 0.6655
55 12 35.29 11 40.74
MG
No 12 35.29 5 18.52 0.15
Yes 21 64.71 22 81.48
Tumor size (cm)
5 4 11.76 5 18.52 0.5379
>5, <8 20 58.82 15 55.56
8 9 29.41 7 25.93
Resectability
Complete 16 50 15 55.56 0.2959
Partial 3 8.82 6 22.22
Unresectable 14 41.18 6 22.22
OP way
No 10 29.41 7 25.93 0.6505
Sternectomy 17 52.94 14 51.85
VATS 6 17.65 6 22.22
RT dose (Gy)
<50 13 41.18 2 7.41 0.0208
50, <60 13 38.24 17 62.96 0.832
60 7 20.59 8 29.63 0.0232
RT fraction
25 10 32.35 2 7.41 0.0191
>25 23 67.65 25 92.59
MGZmyasthenia gravis; OPZ operation; SCVZ supraclavicular; RTZ radiotherapy; VATSZ video-assisted thoracic surgery.
RT for malignant thymoma 115epithelial tumors.10 This system classifies thymic epithelial
tumors into six subtypes: A, AB, B1eB3, and C. At present,
only few papers have tested the prognostic and clinical
validity of the new WHO classification.16e18 Okumura et alreviewed 273 cases of thymic epithelial tumors and classi-
fied them according to the WHO system. Their study sug-
gested that subtypes B2 and B3 tumors had a more
malignant behavior in terms of postoperative survival,
Table 4 Histologic subtypes and the relationship with
resectability and recurrence.
Histologic
subtype
Resection Recurrence
Complete Subtotal
resection
Biopsy
A (nZ 4) 2 0 2 2
AB (nZ 12) 8 4 0 3
B1 (nZ 5) 4 0 2 2
B2 (nZ 5) 4 0 1 2
B3 (nZ 8) 5 1 2 1
C (nZ 25) 8 4 13 8
Total 31 (41.4%) 9 (10.5%) 20 (35.1%) 18
Table 5 Variables analysis of survival, recurrence, and distant
Total Death
(nZ 24)
n p*
Pathology
1 25 15 0.000
Others 35 9
Stage
II 19 1 0.000
III 17 6
IV 24 17
Sex
Female 21 8 0.649
Male 39 16
Karnofsky score
60 14 12 0.000
70 17 6
80 24 6
90 5 0
Systemic disease
No 43 18 0.911
Yes 17 6
Age (y)
<55 37 13 0.131
55 23 11
MG
No 43 18 0.329
Yes 17 6
Tumor size (cm)
5 9 0 0.102
>5, <8 35 16
8 16 8
Resectability
Complete 31 4 0.000
Partial 9 4
Unresectable 20 16
OP way
Biopsy 17 12 0.000
Sternectomy 31 11
VATS 12 1
116 M.-Y. Huang et al.invasiveness, and tumor recurrence, compared with
subtypes A, AB, and B1. In this study, we did not find any
correlation between subtypes A, AB, and B1eB3 and the
risk of aggressiveness (Table 6). When we compared
subtypes A, AB, and B1eB3 with subtype C, the survival rate
reached a statistically significant difference (pZ 0.0003).
Type C had a more invasive oncological behavior than
subtypes A, AB, and B1eB3. The 5- and 10-year survival rate
was 41.7% and 11.7% in type C and 41.7% and 11.7% in
subtypes A, AB, B1eB3.
Another therapeutic issue is the use of RT with or
without chemotherapy. In tumors involving the surrounding
structures, a radical resection is not always possible and
a multidisciplinary approach is required; however, there ismetastasis in malignant thymoma.
Recurrence
(nZ 18)
Distant metastasis
(nZ 15)
n p* n p*
3 8 0.0185 9 0.0055
10 6
1 2 0.0008 0 0.0001
4 2
12 12
6 2 0.21
13
1 8 0.0009 8 0.0003
5 4
5 3
0 0
7 14 0.8253 11 0.7243
4 4
9 12 0.4394 8 0.1495
6 7
12 0.8848 12 0.2204
6 3
6 2 0.8674 1 0.5039
9 10
7 4
1 6 0.0001 2 0.0001
4 1
8 12
1 6 0.0014 8 0.0001
11 6
1 1
Table 5 (continued ).
Total Death
(nZ 24)
Recurrence
(nZ 18)
Distant metastasis
(nZ 15)
n p* n p* n p*
RT dose (Gy)
<50 15 14 0.0001 11 0.0001 7 0.011
50, <60 30 6 5 4
60 15 4 2 4
RT fraction
25 12 10 0.0007 9 0.0001 6 0.0091
>25 48 14 9 9
RT field
Mediastinum 33 18 0.0372 13 0.1492 13 0.0149
Mediastinumþ SCV 27 6 5 2
SCV dose (Gy)
<45 42 20 0.0711 14 0.2351 15 0.0063
45 18 4 4 0
CT
RT alone 46 15 0.0048 10 0.0001 8 0.3787
RTþ CT 14 9 8 7
*p value: value of log rank for survival.
CTZ computed tomography; MGZmyasthenia gravis; OPZ operation; SCVZ supraclavicular; RTZ radiotherapy; VATSZ video-
assisted thoracic surgery.
Table 6 The relationships between pathology and prognosis of malignant thymoma.
Pathology Death (nZ 9) Recurrence (nZ 10) Distant metastasis
(nZ 6)
n p n p n p
Type A 4 2 0.1556 2 0.1196 2 0.1395
Type AB 12 1 3 2
Type B1 6 2 2 1
Type B2 5 2 2 1
Type B3 8 2 1 0
RT for malignant thymoma 117no common agreement about the sequence of different
therapeutic options.
Unfortunately, our study is not a prospective study and
covers a long period of time. Adjuvant chemotherapy was
performed in selected cases of patients with type C and/or
stage III and IV not radically resected. Other experiences
showed that neoadjuvant chemotherapy could improve the
resectability of thymic epithelial tumors or, at least, make
the resection easier, reducing the bulk of tumor and the
vascular or mediastinal infiltration.19,20 The results of 14
patients who received adjuvant chemotherapy showed no
benefit in prognosis.
In conclusion, RT plays a part in the multimodality
therapy of malignant thymoma. Our study showed that high
radiation dose (more than 50 Gy) had significantly increased
survival overall (pZ 0.0001) and decreased distant metas-
tasis (pZ 0.011).
Further and broader studies are needed in order to
verify the utility of prognostic factors in clinical practiceand to improve the therapeutic strategies for patients with
malignant thymomas.Acknowledgments
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